Bioproduction Congress 2022

CMC Readiness to accelerate
biotherapeutics for patients

Agenda

Day 1

Thursday, 29 September 2022

12h20

Registration and welcome coffee

12h50

Welcome Address

13h00

Opening Keynote Lecture

Merck-Serono SA Hervé Broly

Hervé Broly
Executive CMC Consultant for Biologics
Merck-Serono SA, Switzerland

13h30

Track Reassessing Critical quality attributes (CQA ) for mAbs & Vaccines : latest developments

Pierre Fabre Alain Beck

Alain Beck
Senior Director, Biologics CMC & Developability
Pierre Fabre, France
Associate editor
mAbs

RIC group Koen Sandra

Koen Sandra
CEO
RIC group, Belgium

F. Hoffmann-La Roche Ltd. Kowid Ho

Kowid Ho
Technical Regulatory (CMC) Policy Biologics
F. Hoffmann-La Roche Ltd., Switzerland

Track Critical quality attributes (CQA) for Cell & Gene Therapy : new advancements

Yposkesi Olivier Maurion

Olivier Maurion
Director « GoCommercial » Project
Yposkesi, France

Defining CQAs for Cell Based Medicinal Products– The CMC building blocks
Voisin Consulting François Gianelli

François Gianelli
Senior Director CMC
Voisin Consulting

Definition and assessment of quality attributes of a recombinant adeno-associated virus-based gene therapy product
UCB Pharma Michel Degueldre

Michel Degueldre
Lead GT Analytics Physico-Chemical methods
UCB Pharma, Belgium

Real-time monitoring of cell quality attributes drives process intensification in cell and gene therapy
MERCK Antoine Heron

Antoine Heron
Cell & Gene Therapy Bioprocessing
Merck, France

15h00

Coffee Break – Exhibition Hall – B2B Meetings

15h30

Track Process characterization and validation for mAbs and Vaccins : case-studies

Impact of manganese in media components on monoclonal antibodies, lessons learned from dual sourcing & risk mitigation
SANOFI Elodie Lim

Elodie Lim
Upstream Process Engineer
SANOFI & Marine De-Jaeger, SANOFI

Novartis Thibault Lasgouzes

Thibault Lasgouzes
Downstream Process Expert 2
Novartis

Use of Monte-Carlo simulations to check the appropriateness of process parameter acceptable ranges
MERCK Jérôme King

Jérôme King
Biostatisticien
MERCK, Switzerland

Track Process characterization and validation for cell & gene therapy : case-studies

Addressing AAV manufacturing challenges
Celonic Gregory Berger

Gregory Berger
Principal Scientist Cell & Gene Therapy
Celonic, Switzerland

16h30

Breakthrough Innovations in Bioproduction

17h10

Round table: How to bring single-use disposables and consumables suppliers back to Europe: challenges & opportunites

Sartorius Philippe Gomez

Philippe Gomez
Key Account Manager
Sartorius, France

Merck Eva Schaefer

Eva Schaefer
Director Supply Robustness
Merck KGaA, Germany

LFB Biomanufacturing Roland Beliard

Roland Beliard
CEO
LFB Biomanufacturing, France

19h00

Poster presentation- Exhibition Hall – Apero Cocktail

Day 2

Friday, 30 September 2022

8h00

Welcome coffee

8h30

Opening Keynote Lecture

Opportunities for European Biotechs in Africa
Institut Pasteur de Dakar au Sénégal Amadou Sall

Dr. Amadou SALL
CEO
Institut Pasteur de Dakar, Sénégal

9h00

Track Stability studies of cell lines to speed up first in human trials: new technologies & approaches

Use of high advanced technologies to support an efficient cell line generation
Merck Julien Douet

Julien Douet
Head Cell Line Technologies
Merck

Human mesenchymal stem cells for production of extracellular vesicles
Evercyte Regina Grillari

Regina Grillari
COO, CSO, co-founder
Evercyte

Track Viral Clearance in the Manufacture of Biologics: next generation strategies

Sanofi Pasteur Eric Forma

Eric Forma
Scientist - Deputy Head of a Bioprocess Research & Development Unit
Sanofi Pasteur

Sanofi Pasteur Fabien Barbirato

Fabien Barbirato
Technology Innovation Director
Sanofi Pasteur

Sanofi Pasteur Anne Fournillier

Anne Fournillier
Head of CMC Life Cycle Management, Pediatric and Booster vaccines
Sanofi Pasteur

Next generation sequencing as an alternative tool for the detection of potential viruses during the production of biotherapeutics
MERCK Flavio Peroglio

Flavio Peroglio
Head of GMS Ivrea Quality Control & Scientific Excellence
MERCK

ERV removal in CHO cells
Lonza Sandra Bosshard

Sandra Bosshard
Team Lead - cell Culture Development
Lonza, Switzerland

10h20

Coffee Break – Exhibition Hall – B2B Meetings

11h00

Parallell Workshops

12h30

Lunch– Exhibition Hall – B2B Meetings

14h30

Breakthrough Innovations in Bioproduction

15h05

Track mRNA, a new platform technology and therapeutical approach: pros & cons

SANOFI Pasteur Nicolas Chaudet

Nicolas Chaudet
Bioprocess R&D Unit head (microbiology / mRNA)
SANOFI Pasteur

Quantoom Biosciences Jose Castillo

Jose Castillo
CEO
Quantoom Biosciences

New platform platform technology and therapeutic approach – the CDMO and the client perspective
Celonic Arslan Akmammedov

Arslan Akmammedov
Principal Scientist
Celonic

Flash Therapeutics Pascale Bouillé

Pascale Bouillé
CEO
Flash Therapeutics, France

16h30

Closing remarks

16h40

Exhibition Hall – B2B Meetings

18h00

End of Congress

Call for abstracts

Submit your Abstract to give a Pitch presentation or present your Poster at the 7th edition Bioproduction Congress.

In order to provide visibility and promote innovation in the field of “CMC Readiness to accelerate biotherapeutics for patients”, a call is open to submit an abstract for a Pitch at Breakthrough Innovations in Bioproduction Session.
This is a great opportunity for start-ups, SMEs, and academic laboratories to share their new work!

The abstracts will be reviewed and the best selected for innovative products, technology, approaches and research.

Abstract submission deadline: June 17th, 2022

Check out the guidelines and fill-in the Abstract Form and send it to ana-sofia.antunes@mabdesign.fr
Abstract Submission Guidelines Abstract Form

Organization contact